BRCA1 and ovarian carcinoma: For instance, olaparib treatment induced a strong antitumour immune response in different pre-clinical tumour mouse models, including TNBC [56], SCLC [57] and BRCA1-deficient ovarian cancer [20], in a cGAS/STING-dependent manner.